masimo (nasdaq: masi) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. our work is making a measurable difference in the world by saving, extending and improving the lives of people of all ages, in all walks of life for more than 27 years, our innovative medical technologies and noninvasive patient monitoring solutions have been solving ‘unsolvable’ problems. the result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making. masimo is for‘what-ifers’, ‘never-say-never-ers’, and ‘world changers’—people who look beyond what others see. we're looking for people who can, do, and will make a difference. we think you'll like what you see.
Company profile
Ticker
MASI
Exchange
Website
CEO
Joseph Kiani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical • Fonar ...
SEC CIK
Corporate docs
Subsidiaries
Masimo Americas, Inc. • Masimo de Mexico Holdings I LLC • Masimo de Mexico Holdings II LLC • Masimo Holdings LLC • SpO2.com, Inc. • SEDLine, Inc. • Masimo Australia Pty Ltd • Masimo Öesterreich GmbH • Masimo Importacao e Distribuicao de Produtos Medicos Ltda • Masimo Holdings LP ...
IRS number
330368882
MASI stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
31 May 24
DEFA14A
Additional proxy soliciting materials
31 May 24
PREC14A
Preliminary proxy with contested solicitation
31 May 24
SD
Conflict minerals disclosure
23 May 24
DEFA14A
Additional proxy soliciting materials
17 May 24
DEFA14A
Additional proxy soliciting materials
16 May 24
DEFA14A
Additional proxy soliciting materials
13 May 24
DEFA14A
Additional proxy soliciting materials
13 May 24
DFAN14A
Additional proxy materials by non-management
9 May 24
DEFA14A
Additional proxy soliciting materials
9 May 24
Transcripts
MASI
Earnings call transcript
2024 Q1
7 May 24
MASI
Earnings call transcript
2023 Q4
27 Feb 24
MASI
Earnings call transcript
2023 Q3
7 Nov 23
MASI
Earnings call transcript
2023 Q2
8 Aug 23
MASI
Earnings call transcript
2023 Q2
8 Aug 23
MASI
Earnings call transcript
2023 Q1
9 May 23
MASI
Earnings call transcript
2022 Q4
28 Feb 23
MASI
Earnings call transcript
2022 Q3
9 Nov 22
MASI
Earnings call transcript
2022 Q2
10 Aug 22
MASI
Earnings call transcript
2022 Q1
3 May 22
Latest ownership filings
SC 13D/A
Politan Capital Management LP
9 May 24
SC 13D/A
Politan Capital Management LP
8 May 24
4
CRAIG B REYNOLDS
3 May 24
4
CRAIG B REYNOLDS
30 Apr 24
144
Notice of proposed sale of securities
26 Apr 24
SC 13D/A
Politan Capital Management LP
27 Mar 24
4
Blair Tripodi
1 Mar 24
4
Bilal Muhsin
1 Mar 24
4
Tao Levy
1 Mar 24
4
Micah W Young
1 Mar 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jul 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Jan 22 | Jan 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 164.00 mm | 164.00 mm | 164.00 mm | 164.00 mm | 164.00 mm | 164.00 mm |
Cash burn (monthly) | 1.40 mm | 1.43 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 2.94 mm | 2.99 mm | n/a | n/a | n/a | n/a |
Cash remaining | 161.06 mm | 161.01 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 115.0 | 113.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2024
93.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 321 |
Opened positions | 110 |
Closed positions | 44 |
Increased positions | 70 |
Reduced positions | 87 |
13F shares | Current |
---|---|
Total value | 6.94 tn |
Total shares | 49.75 mm |
Total puts | 248.00 k |
Total calls | 183.97 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 7.88 mm | $1.16 tn |
FMR | 6.98 mm | $1.02 tn |
Politan Capital Management | 4.71 mm | $692.18 bn |
Vanguard | 4.56 mm | $669.03 bn |
Capital Research Global Investors | 2.27 mm | $333.24 bn |
Massachusetts Financial Services | 1.72 mm | $252.84 bn |
Farallon Capital Management | 1.49 mm | $218.74 bn |
RTW Investments | 1.46 mm | $214.75 bn |
STT State Street | 1.36 mm | $199.76 bn |
Citadel Advisors | 1.35 mm | $197.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 May 24 | Reynolds Craig B | Common Stock | Option exercise | Acquire M | No | Yes | 23.04 | 10,000 | 230.40 k | 17,406 |
1 May 24 | Reynolds Craig B | NQSO Common Stock | Option exercise | Dispose M | No | No | 23.04 | 10,000 | 230.40 k | 0 |
26 Apr 24 | Reynolds Craig B | Common Stock | Sell | Dispose S | No | Yes | 136.1654 | 40,000 | 5.45 mm | 7,406 |
26 Apr 24 | Reynolds Craig B | Common Stock | Option exercise | Acquire M | No | No | 23.04 | 40,000 | 921.60 k | 47,406 |
26 Apr 24 | Reynolds Craig B | NQSO Common Stock | Option exercise | Dispose M | No | No | 23.04 | 40,000 | 921.60 k | 10,000 |
1 Mar 24 | Blair Tripodi | RSU Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 30,000 |
1 Mar 24 | Blair Tripodi | NQSO Common Stock | Grant | Acquire A | No | No | 126.49 | 9,127 | 1.15 mm | 9,127 |
1 Mar 24 | McClenahan Thomas Samuel | RSU Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 30,000 |
1 Mar 24 | McClenahan Thomas Samuel | NQSO Common Stock | Grant | Acquire A | No | No | 126.49 | 11,954 | 1.51 mm | 11,954 |
1 Mar 24 | Muhsin Bilal | RSU Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 30,000 |
News
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
23 May 24
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
8 May 24
Piper Sandler Maintains Neutral on Masimo, Raises Price Target to $126
8 May 24
Needham Reiterates Hold on Masimo
8 May 24
Masimo Q1 2024 Adj EPS $0.77 Beats $0.69 Estimate, Sales $492.800M Beat $487.554M Estimate
7 May 24
Press releases
Masimo Announces Nomination of Independent Candidate to the Board of Directors
31 May 24
Lowey Dannenberg, P.C. is Investigating Masimo Corporation (NASDAQ: MASI) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
30 May 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Masimo Corporation - MASI
30 May 24
ROSEN, A TOP RANKED LAW FIRM, Encourages Masimo Corporation Investors to Inquire About Securities Class Action Investigation - MASI
29 May 24
Medable and Masimo Partner to Bring Best-in-Class Wearable Devices to Clinical Research, Capturing Rich Subjective and Objective Data
29 May 24